eMedicine from WebMD
 

eMedicine Specialties > Infectious Diseases > Viral Infections

Human T-Cell Lymphotrophic Viruses

Ewa Maria Szczypinska, MD, Fellow, Department of Infectious Diseases, Orlando Health
Mark R Wallace, MD, FACP, FIDSA, Clinical Professor of Medicine, Florida State University College of Medicine; Infectious Disease Fellowship Director, Orlando Regional Medical Center; Booth Wainscoat, DO, Assistant Director, Division of Infectious Disease, Hartford Hospital; Christopher Mark Salas, MD, Resident Physician, Department of Internal Medicine, Maine Medical Center; Josiah D Rich, MD, MPH, Associate Professor, Department of Internal Medicine, Division of Infectious Disease, Brown University School of Medicine

Updated: Nov 19, 2009

Introduction

Background

Human T-cell lymphotropic virus (HTLV) was the first human retrovirus discovered. HTLV belongs to the Retroviridae family in the genus Deltaretrovirus. Retroviruses are RNA viruses that use an enzyme called reverse transcriptase to produce DNA from RNA. The DNA is subsequently incorporated into the host’s genome. HTLV predominantly affects T lymphocytes.

Prior to 1979, the isolation of retroviruses was possible only in nonhuman primates; in fact, it was believed that human retroviruses did not exist. In 2005 in Retrovirology, Gallo reflected about earlier concepts that supported this belief. First, if human retroviruses did in fact exist, then why had they not yet been discovered? Second, the virus was easily detected in animals, and therefore should have also been easily detectable in humans. Third, technical difficulties hampered efforts to grow primary human cells in the laboratory. Finally, it was shown that the human complement lyses animal retroviruses in vitro, suggesting erroneously that humans were intrinsically protected from these viruses.1

In 1979, T-cell lymphotropic virus was isolated in a patient with cutaneous T-cell lymphoma.2 This led to the discovery of the first HTLV and marked the beginning of the human retrovirus era. Two years later, HTLV-2 was documented in a patient who had been diagnosed with hairy cell leukemia,3 although subsequent studies showed no affiliation between the two processes.

In 1983, the third and most important retrovirus was discovered. At the time of its discovery, this virus was classified in the HTLV genus. However, upon further research, it was reclassified into the Lentivirus genus and given the name human immunodeficiency virus (HIV). In 2005, two novel viruses, HTLV-3 and HTLV-4, were discovered. Little is known about these viruses, as only a few cases have been reported.

Now, 30 years later after the initial discovery, 4 HTLVs are well established. HTLV-1 and HTLV-2 are both involved in actively spreading epidemics, affecting 15-20 million people worldwide.4 HTLV-1 is the more clinically significant of the two, as it has been proven to be the etiologic agent of multiple disorders. At least 500,000 of the individuals infected with HTLV-1 eventually develop an often rapidly fatal leukemia, while others will develop a debilitative myelopathy, and yet others will experience uveitis, infectious dermatitis, or another inflammatory disorder. HTLV-2 is associated with milder neurologic disorders and chronic pulmonary infections. The novel HTLV-3 and HTLV-4 have been isolated only in a few cases; no specific illnesses have yet been associated with these viruses.

Pathophysiology

HTLVs are intracellular proviruses that pass through formation of a "virological synapse", allowing the viral genome to be passed from one cell to another. Once infection has occurred, little replication takes place. Infection affects the expression of T-lymphocyte gene expression, leading to increased proliferation of affected T lymphocytes. HTLV primarily affects T lymphocytes: specifically, HTLV-1 predominantly affects CD4 lymphocytes, while HTLV-2 predominantly affects CD8 lymphocytes. In vitro, HTLV-1 is also capable of infecting other cell types, possibly accounting for the diverse pathogenesis of HTLV-1. Recently, GLUT-1, a ubiquitous glucose transporter, has been identified as a receptor for HTLV-15 ; this may explain its ability to infect various cell types.

Acute HTLV infection is rarely seen or diagnosed, as most infections are latent and asymptomatic. Infection might be diagnosed after an attempted blood donation or through workup of a disease caused by the virus. For example, HTLV-1 is associated primarily with two diseases, adult T-cell leukemia (ATL) and HTLV-1–associated myelopathy/tropical spastic paraparesis (HAM/TSP).

HTLV-1 and HTLV-2 have similar transmission patterns, although the transmission efficiency of HTLV-2 is uncertain because of a lack of unbiased data gathering. Both can be transmitted via breast milk, sexual contact, and intravenous drug use, and both can be introduced directly into the vascular system. HTLV-3 and HTLV-4 seem to be transmitted through direct human contact with primates (eg, through hunting, butchering, keeping them as pets), but data are lacking.6

On the molecular level, as with all retroviruses, HTLV has a gag-pol-env motif with flanking long terminal repeat sequences. Unique to the Deltraviruses, however, it includes a fourth sequence named Px, which participates in open-reading–frame transcription, in turn encoding for regulatory proteins Tax, Rex, p12, p13, and p30. All these proteins are important for the infectivity of cells, as well as in stimulating replication. In ATL, the main pathogenic protein, Tax, leads to leukogenesis and immortalization of T lymphocytes in vitro.7 This is achieved by stimulation of interleukin-15 (IL-15) and interleukin-2 (IL-2), in turn leading to T-cell growth and transformation. Research on this subject is ongoing, and the expression of this gene is not always found in ATL cells.8 Furthermore, Tax is inherent to both HTLV-1 and HTLV-2, although HTLV-1 is more pathogenic.9

Recently, the HTLV-1 basic zipper factor gene (HBZ) has been found to be consistently expressed in ATL cells, suggesting a role in cellular transformation and leukemogenesis. This might correlate with the increased pathogenesis of HTLV-1.10 The expression of the HBZ gene also correlates with the provirus load of HTLV-1.

Epidemiology

Because of the low replicating nature of HTLV, the virus develops little genetic sequence variation.4 Therefore, most epidemiologic data are based on serologic studies rather than on molecular typing. Variations exist in the env gene for each HTLV; they define the HTLV subtypes. The distribution of HTLV-1 and HTLV-2 subtypes is quite distinct and can probably be explained by differing evolutionary trends.4 HTLV-1 subtypes are associated with specific regions of the globe, while HTLV-2 subtypes are related to highly specific subpopulations (eg, Brazilian Indians) and behaviors such as injection drug use.

Transmission of HTLV-1 and HTLV-2

  • Breastfeeding
    • HTLV-infected T cells in breast milk pass from mother to child. The risk of HTLV-1 transmission reaches 20% and is affected by the duration of breastfeeding, the proviral load, and the quantity of maternal antibodies. Intrauterine infection is less common, about 5%.11,12,13
    • For HTLV-2, the quantitative risk remains uncertain for both breastfeeding and intrauterine transmission.
  • Sexual: Increased exposure and increased proviral load increase the risk of sexual transmission of both HTLV-1 and HTLV-2.14
  • Transfusion: The risk of seroconversion due to contaminated blood transfusion has been reported to be 40%-60% and increases in immunosuppressed recipients.15
  • Transplant: Reports have documented kidney, liver, and lung transplant transmission of HTLV-1.16
  • Intravenous drug use: This mode of transmission is mostly linked to HTLV-2. The prevalence of HTLV-2 infection in North American injection drug users ranges from 8%-17%.17

HTLV-1

Six different HTLV-1 subclasses exist, and each subtype is endemic to a particular region.4

  • Subtype A (cosmopolitan subtype) - Japan
  • Subtypes B, D, and F - Central Africa
  • Subtype C - Melanesia
  • Subtype E - South and Central Africa

HTLV-1 is associated with the below diseases. Note that ATL and HAM/TSP are generally mutually exclusive, and only a few cases with both disorders have been described.18,19

  • ATL develops in 2%-4% of individuals with HTLV-1 infection.20 Four clinical subtypes of ATL have been described.21
    • The acute form comprises 55%-75% of all ATL cases. It is characterized by a significantly increased white blood cell count that is mostly made up of leukemic T cells. It also features generalized lymphadenopathy.
    • The chronic form is characterized by absolute lymphocytosis (4 × 109/L or more), with T lymphocytosis comprising more than 3.5 × 109/L. These laboratory findings persist for months to years in most patients with chronic ATL. The lymphatic system may become involved.
    • Smoldering ATL is characterized by 5% or more abnormal T lymphocytes in peripheral blood, with a normal total lymphocyte count.
    • The lymphoma type involves generalized lymphadenopathy and an absence of peripheral blood involvement.
  • HAM/TSP develops in 1%-2% of individuals with HTLV-1 infection.20
    • The pathophysiology of HAM/TSP remains unclear, but, clinically, it can be defined as a slowly progressive degenerative disease that primarily affects the corticospinal tracts of the thoracic cord.
    • Major pathologic findings of HAM/TSP may include inflammatory perivascular and parenchymal infiltration by T-lymphocyte cells, leading to degeneration and fibrosis in the spinal cord. The degree of infiltration is less than in other retroviral infections (eg, HIV infection), perhaps because of the slow pathogenesis of the virus.22
    • Immunologic mechanisms may be involved in the development of HAM/TSP. This is likely mediated through autoimmune processes or cytotoxic attack on the HTLV-1–infected cells.
    • A higher provirus load increases not only the overall risk of HAM/TSP but also the likelihood that the disease will progress more quickly.23
    • HTLV-1 is also associated with a broader spectrum of neurologic abnormalities that are not as severe as HAM/TSP. It is not clearly established if individuals with the other neurologic abnormalities will eventually develop HAM/TSP or will remain stable.24
  • HTLV-1–associated uveitis25
    • This is defined as the presence of HTLV viral sequences and HTLV-infected lymphocytes in the vitreous fluid.
    • Additional ocular manifestations in individuals with HTLV-1 infection include retinal vasculitis, choroidopathy, and keratopathy.
  • HTLV-1–associated infective dermatitis
    • HTLV-1–associated infective dermatitis (IDH) is a chronic and severe dermatitis that mainly affects children who have been infected with HTLV via vertical transmission.
    • There is an association between IDH and onset of HAM/TSP; 30% of Brazilian children with IDH develop HAM/TSP in adolescence.23
    • Patients with IDH have a higher proviral load than asymptomatic carriers of HTLV-1. Primo et al (2009) reported that the proviral load was not associated with age, duration of infection, duration of breastfeeding, or severity of skin infection.23
    • Other diseases associated with HTLV-1 include Sjögren syndrome, polymyositis, and chronic inflammatory arthropathy.26,20

HTLV-2

HTLV-2 is classified into 4 molecular subtypes. Each has a characteristic geographic association.

  • Subtypes A and B - Present throughout Western Hemisphere and Europe; sporadic distribution in Asia and Africa
  • Subtype C - Kayapo indigenous people of the Amazon and urban Brazilian populations
  • Subtype D - Discovered in an African pygmy tribe

To date, no conclusive evidence has proven that HTLV-2 is an etiologic agent in any specific disease. However, the following links have been suggested:

  • HTLV-2 infection may result in neurologic manifestations similar to the non-HAM complications of HTLV-1 infection. Recent data suggest that HTLV-1 and HTLV-2 carry similar risks in terms of resulting in non-HAM neurological illness.27,24
  • Case reports have linked HTLV-2 infection with pneumonia, bronchitis, arthritis, asthma, and dermatitis.17

HTLV-3 and HTLV-4

These HTLV subtypes were first isolated in 2005. HTLV-3 was initially isolated from a 62-year-old male pygmy in southern Cameroon.28 Now, with the aid of advancing laboratory technology, new strains are quickly being identified. Individuals infected with HTLV-3 have all been asymptomatic, with a low proviral load. HTLV-4 has been described in African bush meat hunters.

Neither HTLV-3 nor HTLV-4 has been associated with specific diseases thus far, and further research is ongoing. Given the ongoing discovery of subtypes and strains, it is not surprising that 28% of certain populations in central Africa have been reported to have indeterminate HTLV serology results.6

The HTLV-3 label was initially applied to the virus that causes AIDS. However, further research found that the pathogenesis and genetic makeup of the AIDS virus differed from HTLV-1 and HTLV-2. Subsequently, the name was formally changed to HIV.

Frequency

United States

  • HTLV-14  
    • Based on transfusion screening data, the seroprevalence of HTLV-1 infection is 0.01%-0.03%.
    • HTLV-1 infection is primarily limited to immigrants, children of immigrants, sex workers, and injection drug users.
  • HTLV-217  
    • In the United States, HTLV-2 infection predominantly affects Native American Indians. Some tribes have seroprevalence rates as high as 13%.
    • Intravenous drug users, in whom the seroprevalence is estimated to be about 20%, with a disproportionate share occurring in African American injection drug users.

International

  • Areas and small population clusters with high concentrations of HTLV-1 include the following:4  
    • Southwest Japan: Japan has both low and high endemic microregions, with an estimated total 1.2 million HTLV-1 carriers.
    • Caribbean basin (Jamaica and Trinidad): This region has a prevalence of up to 6%.
    • Sub-Saharan African countries (Benin, Cameroon, Guinea-Bissau): These countries have a prevalence of up to 5%.
    • South America
    • The Mashadi Jewish people of northern Iran and various immigrant populations from endemic areas
  • Areas and populations with high concentrations of HTLV-2 include the following: 
    • Central and South America
    • North America and Europe, mainly among intravenous drug users

Mortality/Morbidity

Mortality and morbidity due to HTLV infections are primarily associated with diseases caused by HTLV-1, namely ATL or HAM/TSP.

  • Infected individuals have a cumulative lifetime risk of 1%-4% of developing ATL or HAM/TSP.4 The latency period for ATL is typically 30-50 years. ATL is usually rapidly progressive and fatal, with a median survival time of 2 years.29
  • HAM/TSP can occur as early as 3 months after blood transfusion–related HTLV-1 infection. Three years of latency is more typical, and 20-30 years is possible.
  • Biswas et al (2009) found that patients infected with HTLV - 2 missed more work days than patients with HTLV-1, possibly because of isolated neurological manifestations and the increased rate of upper respiratory infections and arthritis associated with HTLV-2.24

Sex

  • In endemic areas, HTLV-1 seropositivity is clustered in families, especially among women, suggesting that transmission occurs more easily from men to women than from women to children. Determining the sexual predominance of HTLV-2 infection is complicated by intravenous drug use in the study population.
  • Recent findings suggest that vertical transmission has a male predisposition, accounting for the predominance of male HTLV-1 seropositivity in childhood. This, in turn, may explain the increased prevalence of ATL in males because of a longer carrier state.30
  • HAM/TSP disproportionately affects females (with a female-to-male ratio as high as 2:1).4

Age

The prevalence of HTLV-1 and HTLV-2 infections increases with advancing age. The onset of ATL or HAM/TSP is often delayed until later in life because of the prolonged latency state; vertical transmission is associated with an elevated risk of ATL or HAM/TSP.

Clinical

History

Acute human T-cell lymphotropic virus (HTLV) infection is rarely suspected or diagnosed.

Because of the low viral replication of HTLV, there are usually no clinical symptoms. Diagnosis may stem from blood donation, testing performed because of a familial history of the infection, or a workup of adult T-cell leukemia (ATL) or HTLV-1–associated myelopathy/tropical spastic paraparesis (HAM/TSP) in patients with consistent clinical manifestations. Suspected cases may prompt investigation for a history of a recent blood-product transfusion or a nursing mother from an endemic area.

In considering HTLV infection, the most important historical information pertains to risk assessment. Because detecting accurate seroprevalence in low-endemic populations is inherently problematic, it is important to stratify a patient's risk. Screening enzyme immunoassays (EIAs) yield false-positive results in more than 50% of cases in areas of low prevalence. Therefore, a high-risk individual is anyone who has any of the following characteristics:

  • Has lived or lives in an endemic area (ie, Japan, the Caribbean, Central or West Africa, South America)
  • Is a Native American Indian
  • Has parents or sexual partners from an endemic area
  • Received blood-product transfusions in the United States before 1988
  • Has received blood transfusions anywhere that lacks active blood-bank screening
  • Has a history of injection drug use
  • Has sexual partners with a history of injection drug use
  • Has multiple sexual partners and does not use barrier protection
  • Has strongyloidiasis hyperinfection

The sequelae of latent HTLV infection generally occur decades after the initial infection, with the one exception being the reports of HAM/TSP occurring within a few months of HTLV-1–contaminated blood transfusion.31

Patients with HAM/TSP may present with weakness and stiffness in the lower limbs (first presenting symptom in 60% of cases32 ), urinary incontinence, and/or severe lower back pain radiating to the legs. In some cases, urinary frequency, urgency, incontinence, or retention precedes the paraparesis by many years. Infected patients may also have symptoms of autonomic dysfunction leading to constipation, and, in some cases, sexual dysfunction.

Symptoms of ATL are clinically broad and can manifest as fatigue, overt lymphadenopathy, thirst (due to hypercalcemia), nausea, vomiting, fever, or abdominal pain.

Physical

There are no strict criteria established in terms of physical findings of HAM/TSP; however, the following constellation of physical findings are typical and progressively worsen:24

  • Motor and sensory changes in the lower extremities
  • Clonus (may be evident); involuntary muscular contractions upon stretching of the muscles
  • Spastic gait in combination with weakness of the lower limbs
  • Detrusor insufficiency leading to bladder dysfunction
  • Preserved cognitive and upper-extremity neurological functions

The following isolated neurological symptoms have been also described in patients affected with HTLV-1 or HTLV-2:24

  • Sensory neuropathies
  • Gait abnormalities
  • Bladder dysfunction
  • Erectile dysfunction
  • Mild cognitive defects
  • Motor abnormalities

ATL has the following 4 distinct types and clinical characteristics:

  • Acute ATL
    • Short and aggressive clinical course
    • Hypercalcemia, lytic bone lesions, pulmonary involvement, and lymphocytosis
    • Hepatosplenomegaly
    • Cutaneous lesions (indolent, nodular, indurated, exfoliative, or erythrodermal)
  • Smoldering ATL
    • Abnormal lymphocytes of 5% or less
    • Malignant cells with monoclonal proviral integration
    • Skin lesions
    • Pulmonary involvement (occasional)
    • No hypercalcemia, lymphadenopathy, or other visceral involvement
    • Possible elevation of the serum lactase dehydrogenase level
  • Chronic ATL
    • No hypercalcemia, ascites, or pleural effusion
    • No CNS, bone, or GI involvement
    • Possible lymphadenopathy, hepatomegaly, splenomegaly, skin or pulmonary involvement
    • A serum lactate dehydrogenase level that may be twice the reference range
    • Abnormal T-cell lymphocytes, greater than 3.5 X 109/L
    • Absolute lymphocytosis, greater than 4.0 X 109/L
  • Lymphomatous ATL
    • Lymphadenopathy in the absence of lymphocytosis
    • Histologic evidence of lymph node involvement required
    • Skin lesions clinically indistinguishable from cutaneous T-cell lymphomas

Causes

HTLV-1 and HTLV-2 are transmitted vertically from mother to child via breastfeeding or childbirth, from person to person through sexual contact, and through blood contact, either by transfusion or by reuse of injection equipment.

Blood transfusion is very effective at transmitting HTLV-1 and HTLV-2. Screening is standard policy in the United States and in many other countries. The United States has been screening donated blood since 1988.

Differential Diagnoses

Castleman disease
Metastatic disease
Cytomegalovirus
Syphilis
Epstein-Barr virus (EBV) infection
HIV Disease
Lymphoma, Non-Hodgkin

Other Problems to Be Considered

Adult T-cell leukemia (ATL)

Cutaneous T-cell lymphoma
Mycosis fungoides
Sézary syndrome

HTLV-1–associated myelopathy (HAM)32

Multiple sclerosis
Familial spastic paresis
Vitamin B-12 and folate deficiency
Collagen vascular diseases
Endemic regional myelopathies with similar clinical manifestations (schistosomiasis, neurocysticercosis)
Vacuolar myelopathy of HIV infection
Toxic neuropathies
Malnutrition
Epidural abscess
Lyme disease
Autoimmune myelopathies
Carcinomatous meningitis
Transverse myelitis
Sarcoidosis

Workup

Laboratory Studies

  • Human T-cell lymphotropic virus (HTLV)–1 and HTLV-2
    • HTLV-1 and HTLV-2 infections are detected with enzyme-linked immunosorbent assay (ELISA), which then must be confirmed with Western blot, immunofluorescence assay (IFA), or polymerase chain reaction (PCR).
    • HTLV ELISA yields very high false-positive rates in areas of low prevalence. For example, confirmatory testing rules out HTLV infection in 60%-80% of blood donors in whom ELISA is initially positive in nonendemic areas.
    • PCR or EIA with virus-specific synthetic peptides is necessary to distinguish between HTLV-1 and HTLV-2. PCR is also necessary in infants who may have false-positive results because of circulating maternal anti-HTLV antibodies.
    • PCR also quantifies the proviral load, which is frequently used as a marker for progression, especially in HTLV-1–associated myelopathy/tropical spastic paraparesis (HAM/TSP). It is expressed as “the number of HTLV-1 DNA copies per fixed number of peripheral blood mononuclear cells.” As an example, the mean proviral copy number per 10,000 peripheral blood mononuclear cells was found to be 798 in patients with HAM/TSP versus 120 in asymptomatic HTLV-1 carriers.32
  • Patients diagnosed with HTLV-1 or HTLV-2 infection should also undergo the following tests:
    • Screening for HIV should be strongly considered.
    • Routine blood work should include a CBC count with differential and peripheral blood smear, complete chemistry with calcium level, liver function tests, and lactate dehydrogenase.
    • Also recommended are viral hepatitis serology (A, B, C), rapid plasma reagin (RPR), purified protein derivative (PPD), Strongyloides stercoralis serology, and stool examination for ova and parasites.

Imaging Studies

No specific imaging studies are recommended for asymptomatic HTLV infections. However, the following might be considered in aiding in diagnoses/evaluation of HAM/TSP or adult T-cell leukemia (ATL).

  • HAM/TSP: Brain MRI reveals nonspecific periventricular and subcortical white matter lesions in 50%-80% of patients with HAM/TSP; however, these lesions also occur in patients with asymptomatic HTLV-1 infections, and comparisons with controls have not been adequate.32
  • ATL 
    • Chest radiography is important, particularly in patients with ATL, to assess for pulmonary complications, opportunistic infections, and lytic bone lesions.
    • CT scanning of the neck, thorax, abdomen, and pelvis is crucial in assessing for nodal involvement.33 It can also aid in further assessment for opportunistic infections (ie, abscess formation, pneumonia, intestinal infections).

Procedures

Lumbar puncture to evaluate CSF for anti–HTLV-1 antibodies (and/or HTLV-1 proviral load) might be beneficial in establishing a diagnosis of HAM/TSP. The laboratory results often show a mild lymphocyte pleocytosis and increased protein levels. A proviral load ratio of CSF to peripheral blood that exceeds 1 supports a diagnosis of HAM/TSP.32

Serology for HTLV-1, along with histologically (ie, lymph node biopsy) or cytologically proven peripheral T-cell malignancy, is diagnostic of ATL. Furthermore, in indolent ATL (chronic or smoldering), when the cause of the lesion is unknown, a biopsy of a suspicious lesion can be performed for analysis of HTLV-1 provirus integration.33

Histologic Findings

HAM/TSP histopathology of the spinal cord shows perivascular and parenchymal infiltration of T cells, which worsens with the development of atrophy during progression of the disease.32

Peripheral blood smear is required for definitive diagnosis and categorization of ATL. ATL peripheral blood lymphocytes are found to have convoluted nuclei (cloverleaf or flower lymphocytes); provirus can be detected within these malignant cells.

Treatment

Medical Care

No treatment intervention exists for acute or chronic human T-cell lymphotropic virus (HTLV) infection. Thorough neurological and ophthalmologic examinations, in addition to a complete physical examination, should be performed in patients infected with HTLV. Additional blood work should also be performed (see Lab Studies).

All patients with HTLV-1 or HTLV-2 infection should be counseled extensively on the lifelong implications of their infection (see Patient Education).34

The treatment of adult T-cell leukemia (ATL) is the same regardless of the presence or absence of HTLV infection.

  • Treatment should begin immediately in patients diagnosed with the aggressive types of ATL (acute or lymphoma). Patients diagnosed with an indolent type of ATL (chronic or smoldering) should be monitored closely for disease progression. Chronic ATL usually progresses to the acute form within two years.33
  • Chemotherapy is the primary treatment approach. CHOP (cyclophosphamide, doxorubicin [hydroxydaunomycin], vincristine [Oncovin], and prednisone) or a similar regimen is used. However, no known regimen increases the median survival time (2 years). Complete remission can occur, but relapse is common.
  • Other regimens include interferon alfa, topoisomerase inhibitors, zidovudine plus interferon alfa, arsenic trioxide plus interferon alfa, blockade of NF-κB with several experimental agents, and monoclonal antibodies against the IL-2R and other receptors on ATL cells.
  • Allogenic hematopoietic stem cell transplantation has yielded varying results. Miyamura et al (2009) reported on a female patient who developed ATL along with chronic refractory eczema and corneal injury. She was subsequently treated with allogeneic hematopoietic stem cell transplantation. At one year, she had no recurrence of any symptoms. Furthermore, her HTLV-1 proviral load had decreased posttransplant.35
  • It is important to monitor for opportunistic infections in patients with ATL, including cytomegalovirus infection, Pneumocystis carinii infection, S stercoralis infection, Norwegian scabies, disseminated molluscum contagiosum, extrapulmonary histoplasmosis, and complications of staphylococcal and streptococcal skin infections.

HTLV-1–associated myelopathy/tropical spastic paraparesis (HAM/TSP) treatment options are even more limited and focus on symptomatic therapy.

  • Studied therapies have included corticosteroids, plasmapheresis, cyclophosphamide, and interferon, which may produce temporary improvement in signs and symptoms associated with HAM/TSP.
  • Valproic acid has been studied to determine whether it might slow the progression of HAM/TSP by decreasing the proviral load. Although it succeeded in reducing the proviral load, there was no clinical benefit.32 Recently, a combination of valproic acid and zidovudine has been shown to decrease proviral loads in baboons infected with simian T-cell lymphotropic virus (STLV)–1; however, this has yet to be studied in humans with HAM/TSP.36

Consultations

  • Consultation with an infectious disease specialist is advisable to diagnose HTLV infection.
  • A hematologist/oncologist should be consulted for patients with ATL.
  • A neurologist should be consulted for patients with HAM/TSP.
  • An ophthalmologist should be consulted for patients with ocular symptoms and for routine examinations.

Activity

Use of barrier protection during intercourse is important to prevent the sexual spread of HTLV. Also, intravenous drug users should avoid sharing needles.

Medication

No specific treatments have been proven effective specifically for human T-cell lymphotropic virus (HTLV)–1 or HTLV-2 infection.

Antiretroviral agents have demonstrated the ability to inhibit HTLV replication, but there has been limited research in asymptomatic carriers of HTLV-1, in whom the proviral load is already typically low.37 In patients with HTLV-1–associated myelopathy/tropical spastic paraparesis (HAM/TSP), who typically have high HTLV-1 viremia, 6-12 months of zidovudine plus lamivudine failed to show clinical benefit.32

Follow-up

Deterrence/Prevention

Strategies for human T-cell lymphotropic virus (HTLV) infection prevention should include education regarding transmission on a global and individual basis. Both HTLV-1 and HTLV-2 can be transmitted through breastfeeding, sexual contact, and direct blood-to-blood contact.

  • Women diagnosed with HTLV infection should not breast feed. In Japan, HTLV screening is a standard procedure in pregnant women, and seropositive women are discouraged from breastfeeding. One caveat is that infant malnutrition result from breastfeeding avoidance in endemic developing nations.
  • The routine use of latex condoms should be recommended, as well as limiting the number of sexual partners.
  • Parenteral transmission of HTLV is prevented through abstaining from needle sharing and through blood-donor screening.

Complications

Complications of HTLV infection are due mostly to end-stage diseases rather than to the infection itself, as the vast majority of individuals with this infection are asymptomatic. However, the following should be kept in consideration:

  • HTLV-1 is a risk factor for the development of severe strongyloidiasis; close follow-up of patients following treatment for strongyloidiasis is recommended.38
  • Patients with adult T-cell leukemia (ATL) are immunocompromised, potentially leading to opportunistic infections including the following:
    • Pneumocystis jiroveci pneumonia: Prophylaxis with sulfamethoxazole-trimethoprim should be initiated.
    • Cryptococcal meningitis
    • Fungal infections
    • Viral infections (eg, cytomegalovirus, herpes zoster, herpes simplex)
    • S stercoralis infection: Prophylaxis with ivermectin or albendazole should be considered in patients with a history of past or present exposure or positive serology results.38

Co-infection of either HTLV-1 or HTLV-2 with HIV remains a controversial topic.

  • Conclusive and reproducible data of such coinfections are not yet available, as most of the data are limited by the testing methodology.
  • Theoretically, HTLV-1 and HIV affect the same cell type, and the additive result might be detrimental to the immune system, leading to faster progression to AIDS. Future research might lead to recommendations concerning coinfections (eg, starting HAART or prophylaxis for opportunistic infections); however, no specific guidelines exist at this time. A recent retrospective cohort study of Peruvian men with HIV/HTLV-1 coinfection did not show that coinfection increased the risk of death.39 This area remains controversial, as some studies show an unfavorable outcome for HIV/HTLV-1 coinfection, while others do not.
  • No evidence has shown that HIV/HTLV-2 coinfection leads to faster progression to AIDS; in fact, coinfection might have some protective effects based on in vitro studies.40

Prognosis

  • Infection with HTLV-1 or HTLV-2 is lifelong, and most (95%) infected individuals remain asymptomatic throughout life, without progression to any end-point diseases.
  • The latency period for ATL is about 20-40 years. Patients with smoldering and chronic type ATL live an average of 2 years, and those with acute and lymphoma-type ATL live an average of 6 months. Chemotherapy or interferon plus antiretroviral drugs can produce complete remission, but the median survival remains under 2 years.
  • HTLV-1–associated myelopathy/tropical spastic paraparesis (HAM/TSP) carries a poor prognosis. The latency period ranges from a few months to 30 years postinfection. Within 10 years of onset, despite therapy, most patients are unable to walk unassisted and are wheelchair-bound within 21 years.32

Patient Education

  • Patients determined to have infection with any subtype of HTLV should share this information with their physicians and undergo regular follow-up.
  • Education should focus on preventing transmission to others through unprotected sexual activity. Sexual partners of patients with HTLV-1 infection who are in a mutually monogamous sexual relationship should consider being tested. If the partner is positive then no further recommendation is warranted. If the partner is negative, then the use of latex condoms is advised. Specific testing guidelines for partners of HTLV-2 infected individuals have not been established.
  • Patients should be instructed to avoid sharing needles.
  • Women with HTLV-1 or HTLV-2 infection should not breast feed their infants. If this is unfeasible (ie, women in undeveloped countries), breastfeeding should be limited to the first 6 months.
  • Patients should be counseled against donating blood, body organs, or tissues
  • Patients with HTLV-1 infection should be informed about the 1&-6% lifetime chance of developing ATL or HAM/TSP.

References

  1. Gallo RC. The discovery of the first human retrovirus: HTLV-1 and HTLV-2. Retrovirology. Mar 2 2005;2:17. [Medline].

  2. Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci U S A. Dec 1980;77(12):7415-9. [Medline].

  3. Kalyanaraman VS, Sarngadharan MG, Robert-Guroff M, Miyoshi I, Golde D, Gallo RC. A new subtype of human T-cell leukemia virus (HTLV-II) associated with a T-cell variant of hairy cell leukemia. Science. Nov 5 1982;218(4572):571-3. [Medline].

  4. Proietti FA, Carneiro-Proietti AB, Catalan-Soares BC, Murphy EL. Global epidemiology of HTLV-I infection and associated diseases. Oncogene. Sep 5 2005;24(39):6058-68. [Medline].

  5. Manel N, Kim FJ, Kinet S, Taylor N, Sitbon M, Battini JL. The ubiquitous glucose transporter GLUT-1 is a receptor for HTLV. Cell. Nov 14 2003;115(4):449-59. [Medline].

  6. Wolfe ND, Heneine W, Carr JK, Garcia AD, Shanmugam V, Tamoufe U. Emergence of unique primate T-lymphotropic viruses among central African bushmeat hunters. Proc Natl Acad Sci U S A. May 31 2005;102(22):7994-9. [Medline].

  7. Boxus M, Twizere JC, Legros S, Dewulf JF, Kettmann R, Willems L. The HTLV-1 Tax interactome. Retrovirology. Aug 14 2008;5:76. [Medline].

  8. Takeda S, Maeda M, Morikawa S, et al. Genetic and epigenetic inactivation of tax gene in adult T-cell leukemia cells. Int J Cancer. Apr 20 2004;109(4):559-67. [Medline].

  9. Feuer G, Green PL. Comparative biology of human T-cell lymphotropic virus type 1 (HTLV-1) and HTLV-2. Oncogene. Sep 5 2005;24(39):5996-6004. [Medline].

  10. Matsuoka M, Jeang KT. Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation. Nat Rev Cancer. Apr 2007;7(4):270-80. [Medline].

  11. Li HC, Biggar RJ, Miley WJ, Maloney EM, Cranston B, Hanchard B. Provirus load in breast milk and risk of mother-to-child transmission of human T lymphotropic virus type I. J Infect Dis. Oct 1 2004;190(7):1275-8. [Medline].

  12. Wiktor SZ, Pate EJ, Rosenberg PS, Barnett M, Palmer P, Medeiros D. Mother-to-child transmission of human T-cell lymphotropic virus type I associated with prolonged breast-feeding. J Hum Virol. Nov-Dec 1997;1(1):37-44. [Medline].

  13. Kinoshita K, Amagasaki T, Hino S, et al. Milk-borne transmission of HTLV-I from carrier mothers to their children. Jpn J Cancer Res. Jul 1987;78(7):674-80. [Medline].

  14. Roucoux DF, Murphy EL. The epidemiology and disease outcomes of human T-lymphotropic virus type II. AIDS Rev. Jul-Sep 2004;6(3):144-54. [Medline].

  15. Manns A, Wilks RJ, Murphy EL, et al. A prospective study of transmission by transfusion of HTLV-I and risk factors associated with seroconversion. Int J Cancer. Jul 30 1992;51(6):886-91. [Medline].

  16. Yara S, Fujita J, Date H. Transmission of human T-lymphotropic virus type I by bilateral living-donor lobar lung transplantation. J Thorac Cardiovasc Surg. Jul 2009;138(1):255-6. [Medline].

  17. Zunt JR, Tapia K, Thiede H, Lee R, Hagan H. HTLV-2 infection in injection drug users in King County, Washington. Scand J Infect Dis. 2006;38(8):654-63. [Medline].

  18. Murata M, Mizusawa H, Kanazawa I, Yazawa T, Uchida Y. [An autopsy case of HTLV-I associated myelopathy (HAM) with adult T-cell leukemia (ATL)]. Rinsho Shinkeigaku. Jul 1990;30(7):754-9. [Medline].

  19. Furukawa Y, Okadome T, Tara M, Niina K, Izumo S, Osame M. Human T-cell lymphotropic virus type-I (HTLV-I)-associated myelopathy/tropical spastic paraparesis with acute type of adult T-cell leukemia. Intern Med. Nov 1995;34(11):1130-3. [Medline].

  20. Murphy EL, Biswas HH. Human T-cell lymphotropic virus types I and II. In: Mandell G, Bennett J, Dolin R, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 7th ed. Philadelphia, PA: Churchill Livingston / Elsevier; 2010:Ch 168.

  21. Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87). Br J Haematol. Nov 1991;79(3):428-37. [Medline].

  22. Alberti C, Gonzalez J, Maldonado H, et al. Comparative study of CSF neurofilaments in HTLV-1-associated myelopathy/tropical spastic paraparesis and other neurological disorders. AIDS Res Hum Retroviruses. Aug 2009;25(8):803-9. [Medline].

  23. Primo J, Siqueira I, Nascimento MC, et al. High HTLV-1 proviral load, a marker for HTLV-1 associated myelopathy/tropical spastic paraparesis, is also detected in patients with infective dermatitis associated with HTLV-1. Braz J Med Biol Res. Aug 2009;42(8):761-4. [Medline].

  24. Biswas HH, Engstrom JW, Kaidarova Z, et al. Neurologic abnormalities in HTLV-I- and HTLV-II-infected individuals without overt myelopathy. Neurology. Sep 8 2009;73(10):781-9. [Medline].

  25. Buggage RR. Ocular manifestations of human T-cell lymphotropic virus type 1 infection. Curr Opin Ophthalmol. Dec 2003;14(6):420-5. [Medline].

  26. Nishioka K, Maruyama I, Sato K, Kitajima I, Nakajima Y, Osame M. Chronic inflammatory arthropathy associated with HTLV-I. Lancet. Feb 25 1989;1(8635):441. [Medline].

  27. Dooneief G, Marlink R, Bell K, et al. Neurologic consequences of HTLV-II infection in injection-drug users. Neurology. Jun 1996;46(6):1556-60. [Medline].

  28. Calattini S, Chevalier SA, Duprez R, Bassot S, Froment A, Mahieux R. Discovery of a new human T-cell lymphotropic virus (HTLV-3) in Central Africa. Retrovirology. 2005;2:30. [Medline].

  29. Yasunaga J, Matsuoka M. Human T-cell leukemia virus type I induces adult T-cell leukemia: from clinical aspects to molecular mechanisms. Cancer Control. Apr 2007;14(2):133-40. [Medline].

  30. Eshima N, Iwata O, Iwata S, et al. Age and gender specific prevalence of HTLV-1. J Clin Virol. Jun 2009;45(2):135-8. [Medline].

  31. Gout O, Baulac M, Gessain A, et al. Rapid development of myelopathy after HTLV-I infection acquired by transfusion during cardiac transplantation. N Engl J Med. Feb 8 1990;322(6):383-8. [Medline].

  32. Cooper SA, van der Loeff MS, Taylor GP. The neurology of HTLV-1 infection. Pract Neurol. Feb 2009;9(1):16-26. [Medline].

  33. Tsukasaki K, Hermine O, Bazarbachi A, et al. Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting. J Clin Oncol. Jan 20 2009;27(3):453-9. [Medline].

  34. [Guideline] Khabbaz RF, Fukuda K, Kaplan JE. Guidelines for counseling human T-lymphotropic virus type I (HTLV-I)- and HTLV type II-infected persons. Transfusion. Aug 1993;33(8):694. [Medline].

  35. Miyamura F, Kako S, Yamagami H, et al. Successful treatment of young-onset adult T cell leukemia/lymphoma and preceding chronic refractory eczema and corneal injury by allogeneic hematopoietic stem cell transplantation. Int J Hematol. Aug 25 2009;[Medline].

  36. Willems L. The 14th International Conference on Human Retrovirology: HTLV and related retroviruses (July 1-4, 2009; Salvador, Brazil). Retrovirology. Aug 17 2009;6:77. [Medline].

  37. Macchi B, Balestrieri E, Mastino A. Effects of nucleoside-based antiretroviral chemotherapy on human T cell leukaemia/lymphotropic virus type 1 (HTLV-1) infection in vitro. J Antimicrob Chemother. Jun 2003;51(6):1327-30. [Medline].

  38. Carvalho EM, Da Fonseca Porto A. Epidemiological and clinical interaction between HTLV-1 and Strongyloides stercoralis. Parasite Immunol. Nov-Dec 2004;26(11-12):487-97. [Medline].

  39. Collins JA, Hernandez AV, Hidalgo JA, Salazar R. HTLV-I infection is not associated with a higher risk of death in Peruvian HIV-infected patients. Rev Inst Med Trop Sao Paulo. Jul-Aug 2009;51(4):197-201. [Medline].

  40. Brites C, Sampalo J, Oliveira A. HIV/human T-cell lymphotropic virus coinfection revisited: impact on AIDS progression. AIDS Rev. Jan-Mar 2009;11(1):8-16. [Medline].

  41. Andrade TM, Dourado I, Galvao-Castro B. Associations among HTLV-I, HTLV-II, and HIV in injecting drug users in Salvador, Brazil. J Acquir Immune Defic Syndr Hum Retrovirol. Jun 1 1998;18(2):186-7. [Medline].

  42. Aye MM, Matsuoka E, Moritoyo T, et al. Histopathological analysis of four autopsy cases of HTLV-I-associated myelopathy/tropical spastic paraparesis: inflammatory changes occur simultaneously in the entire central nervous system. Acta Neuropathol. Sep 2000;100(3):245-52. [Medline].

  43. Beilke MA, Japa S, Moeller-Hadi C, Martin-Schild S. Tropical spastic paraparesis/human T leukemia virus type 1-associated myelopathy in HIV type 1-coinfected patients. Clin Infect Dis. Sep 15 2005;41(6):e57-63. [Medline].

  44. Berger JR, Svenningsson A, Raffanti S, Resnick L. Tropical spastic paraparesis-like illness occurring in a patient dually infected with HIV-1 and HTLV-II. Neurology. Jan 1991;41(1):85-7. [Medline].

  45. Borg A, Yin JA, Johnson PR, Tosswill J, Saunders M, Morris D. Successful treatment of HTLV-1-associated acute adult T-cell leukaemia lymphoma by allogeneic bone marrow transplantation. Br J Haematol. Sep 1996;94(4):713-5. [Medline].

  46. Castilla J, Pachon I, Gonzalez MP, et al. Seroprevalence of HIV and HTLV in a representative sample of the Spanish population. Epidemiol Infect. Aug 2000;125(1):159-62. [Medline].

  47. Cavrois M, Gessain A, Gout O, Wain-Hobson S, Wattel E. Common human T cell leukemia virus type 1 (HTLV-1) integration sites in cerebrospinal fluid and blood lymphocytes of patients with HTLV-1-associated myelopathy/tropical spastic paraparesis indicate that HTLV-1 crosses the blood-brain barrier via clonal HTLV-1-infected cells. J Infect Dis. Oct 2000;182(4):1044-50. [Medline].

  48. Edlich RF, Arnette JA, Williams FM. Global epidemic of human T-cell lymphotropic virus type-I (HTLV-I). J Emerg Med. Jan 2000;18(1):109-19. [Medline].

  49. Gessain A, Barin F, Vernant JC, et al. Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet. Aug 24 1985;2(8452):407-10. [Medline].

  50. Grassmann R, Berchtold S, Radant I, Alt M, Fleckenstein B, Sodroski JG. Role of human T-cell leukemia virus type 1 X region proteins in immortalization of primary human lymphocytes in culture. J Virol. Jul 1992;66(7):4570-5. [Medline].

  51. Hall WW, Takahashi H, Liu C, Kaplan MH, Scheewind O, Ijichi S. Multiple isolates and characteristics of human T-cell leukemia virus type II. J Virol. Apr 1992;66(4):2456-63. [Medline].

  52. Haoudi A, Daniels RC, Wong E, Kupfer G, Semmes OJ. Human T-cell leukemia virus-I tax oncoprotein functionally targets a subnuclear complex involved in cellular DNA damage-response. J Biol Chem. Sep 26 2003;278(39):37736-44. [Medline].

  53. Hershow RC, Galai N, Fukuda K, Graber J, Vlahov D, Rezza G. An international collaborative study of the effects of coinfection with human T-lymphotropic virus type II on human immunodeficiency virus type 1 disease progression in injection drug users. J Infect Dis. Aug 1996;174(2):309-17. [Medline].

  54. Hinuma Y, Nagata K, Hanaoka M, Nakai M, Matsumoto T, Kinoshita KI. Adult T-cell leukemia: antigen in an ATL cell line and detection of antibodies to the antigen in human sera. Proc Natl Acad Sci U S A. Oct 1981;78(10):6476-80. [Medline].

  55. Hisada M, Maloney EM, Sawada T, Miley WJ, Palmer P, Hanchard B. Virus markers associated with vertical transmission of human T lymphotropic virus type 1 in Jamaica. Clin Infect Dis. Jun 15 2002;34(12):1551-7. [Medline].

  56. Hjelle B, Zhu SW, Takahashi H, Ijichi S, Hall WW. Endemic human T cell leukemia virus type II infection in southwestern US Indians involves two prototype variants of virus. J Infect Dis. Sep 1993;168(3):737-40. [Medline].

  57. Iga M, Okayama A, Stuver S, Matsuoka M, Mueller N, Aoki M. Genetic evidence of transmission of human T cell lymphotropic virus type 1 between spouses. J Infect Dis. Mar 1 2002;185(5):691-5. [Medline].

  58. Igakura T, Stinchcombe JC, Goon PK, Taylor GP, Weber JN, Griffiths GM. Spread of HTLV-I between lymphocytes by virus-induced polarization of the cytoskeleton. Science. Mar 14 2003;299(5613):1713-6. [Medline].

  59. Jeang KT. Functional activities of the human T-cell leukemia virus type I Tax oncoprotein: cellular signaling through NF-kappa B. Cytokine Growth Factor Rev. Jun-Sep 2001;12(2-3):207-17. [Medline].

  60. Jeffery KJ, Usuku K, Hall SE, Matsumoto W, Taylor GP, Procter J. HLA alleles determine human T-lymphotropic virus-I (HTLV-I) proviral load and the risk of HTLV-I-associated myelopathy. Proc Natl Acad Sci U S A. Mar 30 1999;96(7):3848-53. [Medline].

  61. Kannagi M, Ohashi T, Harashima N, Hanabuchi S, Hasegawa A. Immunological risks of adult T-cell leukemia at primary HTLV-I infection. Trends Microbiol. Jul 2004;12(7):346-52. [Medline].

  62. LaGrenade L, Hanchard B, Fletcher V, Cranston B, Blattner W. Infective dermatitis of Jamaican children: a marker for HTLV-I infection. Lancet. Dec 1 1990;336(8727):1345-7. [Medline].

  63. Lee HH, Weiss SH, Brown LS, Mildvan D, Shorty V, Saravolatz L. Patterns of HIV-1 and HTLV-I/II in intravenous drug abusers from the middle atlantic and central regions of the USA. J Infect Dis. Aug 1990;162(2):347-52. [Medline].

  64. Lezin A, Olindo S, Oliere S, et al. Human T lymphotropic virus type I (HTLV-I) proviral load in cerebrospinal fluid: a new criterion for the diagnosis of HTLV-I-associated myelopathy/tropical spastic paraparesis?. J Infect Dis. Jun 1 2005;191(11):1830-4. [Medline].

  65. Loughran TP Jr, Coyle T, Sherman MP, et al. Detection of human T-cell leukemia/lymphoma virus, type II, in a patient with large granular lymphocyte leukemia. Blood. Sep 1 1992;80(5):1116-9. [Medline].

  66. Marcos LA, Terashima A, Dupont HL, Gotuzzo E. Strongyloides hyperinfection syndrome: an emerging global infectious disease. Trans R Soc Trop Med Hyg. Apr 2008;102(4):314-8. [Medline].

  67. Martin MP, Biggar RJ, Hamlin-Green G, Staal S, Mann D. Large granular lymphocytosis in a patient infected with HTLV-II. AIDS Res Hum Retroviruses. Aug 1993;9(8):715-9. [Medline].

  68. Matsuoka M. Human T-cell leukemia virus type I (HTLV-I) infection and the onset of adult T-cell leukemia (ATL). Retrovirology. 2005;2:27. [Medline].

  69. Melo J, Beby-Defaux A, Faria C, et al. HIV and HTLV prevalences among women seen for sexually transmitted diseases or pregnancy follow-up in Maputo, Mozambique. J Acquir Immune Defic Syndr. Feb 1 2000;23(2):203-4. [Medline].

  70. Mori N, Yamada Y, Ikeda S, Yamasaki Y, Tsukasaki K, Tanaka Y. Bay 11-7082 inhibits transcription factor NF-kappaB and induces apoptosis of HTLV-I-infected T-cell lines and primary adult T-cell leukemia cells. Blood. Sep 1 2002;100(5):1828-34. [Medline].

  71. Murphy EL, Mahieux R, de The G, et al. Molecular epidemiology of HTLV-II among United States blood donors and intravenous drug users: an age-cohort effect for HTLV-II RFLP type aO. Virology. Mar 15 1998;242(2):425-34. [Medline].

  72. Murphy EL, Wang B, Sacher RA, Fridey J, Smith JW, Nass CC. Respiratory and urinary tract infections, arthritis, and asthma associated with HTLV-I and HTLV-II infection. Emerg Infect Dis. Jan 2004;10(1):109-16. [Medline].

  73. Murphy EL, Watanabe K, Nass CC, Ownby H, Williams A, Nemo G. Evidence among blood donors for a 30-year-old epidemic of human T lymphotropic virus type II infection in the United States. J Infect Dis. Dec 1999;180(6):1777-83. [Medline].

  74. Nasr R, El-Sabban ME, Karam JA, et al. Efficacy and mechanism of action of the proteasome inhibitor PS-341 in T-cell lymphomas and HTLV-I associated adult T-cell leukemia/lymphoma. Oncogene. Jan 13 2005;24(3):419-30. [Medline].

  75. Ohashi T, Hanabuchi S, Kato H, Tateno H, Takemura F, Tsukahara T. Prevention of adult T-cell leukemia-like lymphoproliferative disease in rats by adoptively transferred T cells from a donor immunized with human T-cell leukemia virus type 1 Tax-coding DNA vaccine. J Virol. Oct 2000;74(20):9610-6. [Medline].

  76. Orland JR, Wang B, Wright DJ, Nass CC, Garratty G, Smith JW. Increased mortality associated with HTLV-II infection in blood donors: a prospective cohort study. Retrovirology. 2004;1:4. [Medline].

  77. Osame M, Usuku K, Izumo S, Ijichi N, Amitani H, Igata A. HTLV-I associated myelopathy, a new clinical entity. Lancet. May 3 1986;1(8488):1031-2. [Medline].

  78. Pawson R, Schulz TF, Matutes E, Catovsky D. The human T-cell lymphotropic viruses types I/II are not involved in T prolymphocytic leukemia and large granular lymphocytic leukemia. Leukemia. Aug 1997;11(8):1305-11. [Medline].

  79. Poiesz B, Dube D, Dube S, et al. HTLV-II-associated cutaneous T-cell lymphoma in a patient with HIV-1 infection. N Engl J Med. Mar 30 2000;342(13):930-6. [Medline].

  80. Portis T, Harding JC, Ratner L. The contribution of NF-kappa B activity to spontaneous proliferation and resistance to apoptosis in human T-cell leukemia virus type 1 Tax-induced tumors. Blood. Aug 15 2001;98(4):1200-8. [Medline].

  81. Porto AF, Santos SB, Muniz AL, Basilio V, Rodrigues W Jr, Neva FA. Helminthic infection down-regulates type 1 immune responses in human T cell lymphotropic virus type 1 (HTLV-1) carriers and is more prevalent in HTLV-1 carriers than in patients with HTLV-1-associated myelopathy/tropical spastic paraparesis. J Infect Dis. Feb 15 2005;191(4):612-8. [Medline].

  82. Primo JR, Brites C, Oliveira Mde F, Moreno-Carvalho O, Machado M, Bittencourt AL. Infective dermatitis and human T cell lymphotropic virus type 1-associated myelopathy/tropical spastic paraparesis in childhood and adolescence. Clin Infect Dis. Aug 15 2005;41(4):535-41. [Medline].

  83. Rosenblatt JD, Giorgi JV, Golde DW, et al. Integrated human T-cell leukemia virus II genome in CD8 + T cells from a patient with "atypical" hairy cell leukemia: evidence for distinct T and B cell lymphoproliferative disorders. Blood. Feb 1988;71(2):363-9. [Medline].

  84. Roucoux DF, Wang B, Smith D, et al. A prospective study of sexual transmission of human T lymphotropic virus (HTLV)-I and HTLV-II. J Infect Dis. May 1 2005;191(9):1490-7. [Medline].

  85. Rous P. Landmark article (JAMA 1911;56:198). Transmission of a malignant new growth by means of a cell-free filtrate. By Peyton Rous. JAMA. Sep 16 1983;250(11):1445-9. [Medline].

  86. Safaeian M, Wilson LE, Taylor E, Thomas DL, Vlahov D. HTLV-II and bacterial infections among injection drug users. J Acquir Immune Defic Syndr. Aug 15 2000;24(5):483-7. [Medline].

  87. Salemi M, Lewis M, Egan JF, Hall WW, Desmyter J, Vandamme AM. Different population dynamics of human T cell lymphotropic virus type II in intravenous drug users compared with endemically infected tribes. Proc Natl Acad Sci U S A. Nov 9 1999;96(23):13253-8. [Medline].

  88. Seiki M, Hattori S, Yoshida M. Human adult T-cell leukemia virus: molecular cloning of the provirus DNA and the unique terminal structure. Proc Natl Acad Sci U S A. Nov 1982;79(22):6899-902. [Medline].

  89. Shuh M, Beilke M. The human T-cell leukemia virus type 1 (HTLV-1): new insights into the clinical aspects and molecular pathogenesis of adult T-cell leukemia/lymphoma (ATLL) and tropical spastic paraparesis/HTLV-associated myelopathy (TSP/HAM). Microsc Res Tech. Nov 2005;68(3-4):176-96. [Medline].

  90. Tajima K. Worldwide distribution of HTLV. Jpn J Cancer Res. Jan 1998;89(1):inside front cover. [Medline].

  91. Taylor GP, Matsuoka M. Natural history of adult T-cell leukemia/lymphoma and approaches to therapy. Oncogene. Sep 5 2005;24(39):6047-57. [Medline].

  92. Telzak EE, Hershow R, Kalish LA, et al. Seroprevalence of HTLV-I and HTLV-II among a cohort of HIV-infected women and women at risk for HIV infection. Women's Interagency HIV Study. J Acquir Immune Defic Syndr Hum Retrovirol. Dec 15 1998;19(5):513-8. [Medline].

  93. Temin HM, Mizutani S. RNA-dependent DNA polymerase in virions of Rous sarcoma virus. Nature. Jun 27 1970;226(5252):1211-3. [Medline].

  94. Tsukasaki K, Maeda T, Arimura K, Taguchi J, Fukushima T, Miyazaki Y. Poor outcome of autologous stem cell transplantation for adult T cell leukemia/lymphoma: a case report and review of the literature. Bone Marrow Transplant. Jan 1999;23(1):87-9. [Medline].

  95. Uchiyama T, Yodoi J, Sagawa K, Takatsuki K, Uchino H. Adult T-cell leukemia: clinical and hematologic features of 16 cases. Blood. Sep 1977;50(3):481-92. [Medline].

  96. Utsunomiya A, Miyazaki Y, Takatsuka Y, Hanada S, Uozumi K, Yashiki S. Improved outcome of adult T cell leukemia/lymphoma with allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. Jan 2001;27(1):15-20. [Medline].

  97. Vine AM, Witkover AD, Lloyd AL, Jeffery KJ, Siddiqui A, Marshall SE. Polygenic control of human T lymphotropic virus type I (HTLV-I) provirus load and the risk of HTLV-I-associated myelopathy/tropical spastic paraparesis. J Infect Dis. Oct 1 2002;186(7):932-9. [Medline].

  98. Waldmann TA, White JD, Goldman CK, Top L, Grant A, Bamford R. The interleukin-2 receptor: a target for monoclonal antibody treatment of human T-cell lymphotrophic virus I-induced adult T-cell leukemia. Blood. Sep 15 1993;82(6):1701-12. [Medline].

  99. Yoshida M. Multiple viral strategies of HTLV-1 for dysregulation of cell growth control. Annu Rev Immunol. 2001;19:475-96. [Medline].

  100. Zhang Z, Zhang M, Ravetch JV, Goldman C, Waldmann TA. Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD2 monoclonal antibody, MEDI-507. Blood. Jul 1 2003;102(1):284-8. [Medline].

Keywords

human T-cell lymphotrophic viruses, HTLV, lymphotropic virus, HTLV-1, HTLV-2, HTLV-3, HTLV-4, human T-cell leukemia/lymphoma virus, adult T-cell leukemia virus, ATLV, adult T-cell leukemia, ATL, HTLV-1–associated myelopathy, HAM, tropical spastic paraparesis, TSP, HTLV I/II, gibbon ape leukemia virus, gibbon ape leukemic virus, GALV, bovine leukemic virus, bovine leukemia virus, BLV

Contributor Information and Disclosures

Author

Ewa Maria Szczypinska, MD, Fellow, Department of Infectious Diseases, Orlando Health
Ewa Maria Szczypinska, MD is a member of the following medical societies: American College of Physicians, American Medical Association, and Infectious Diseases Society of America
Disclosure: Nothing to disclose.

Coauthor(s)

Mark R Wallace, MD, FACP, FIDSA, Clinical Professor of Medicine, Florida State University College of Medicine; Infectious Disease Fellowship Director, Orlando Regional Medical Center
Mark R Wallace, MD, FACP, FIDSA is a member of the following medical societies: American College of Physicians, American Medical Association, American Society of Tropical Medicine and Hygiene, and Infectious Diseases Society of America
Disclosure: Nothing to disclose.

Booth Wainscoat, DO, Assistant Director, Division of Infectious Disease, Hartford Hospital
Booth Wainscoat, DO is a member of the following medical societies: Infectious Diseases Society of America
Disclosure: Merck Honoraria Speaking and teaching

Christopher Mark Salas, MD, Resident Physician, Department of Internal Medicine, Maine Medical Center
Disclosure: Nothing to disclose.

Josiah D Rich, MD, MPH, Associate Professor, Department of Internal Medicine, Division of Infectious Disease, Brown University School of Medicine
Josiah D Rich, MD, MPH is a member of the following medical societies: American College of Physicians, American Federation for Medical Research, American Medical Association, American Public Health Association, Infectious Diseases Society of America, Massachusetts Medical Society, and Rhode Island Medical Society
Disclosure: Nothing to disclose.

Medical Editor

Joseph Richard Masci, MD, Chief of Infectious Diseases, Associate Director, Associate Professor, Department of Internal Medicine, Division of Infectious Diseases, Elmhurst Hospital Center, Mount Sinai School of Medicine
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: eMedicine Salary Employment

Managing Editor

Joseph F John Jr, MD, FACP, FIDSA, FSHEA, Clinical Professor of Medicine, Molecular Genetics and Microbiology, Medical University of South Carolina; Associate Chief of Staff for Education, Ralph H Johnson Veterans Affairs Medical Center
Disclosure: BioMerieux Honoraria Review panel membership; Cubist Honoraria Review panel membership; Pfizer Honoraria Speaking and teaching; Merck Stock dividends stock holdings

CME Editor

Eleftherios Mylonakis, MD, Clinical and Research Fellow, Department of Internal Medicine, Division of Infectious Diseases, Massachusetts General Hospital
Eleftherios Mylonakis, MD is a member of the following medical societies: American Association for the Advancement of Science, American College of Physicians, American Society for Microbiology, and Infectious Diseases Society of America
Disclosure: Nothing to disclose.

Chief Editor

Burke A Cunha, MD, Professor of Medicine, State University of New York School of Medicine at Stony Brook; Chief, Infectious Disease Division, Winthrop-University Hospital
Burke A Cunha, MD is a member of the following medical societies: American College of Chest Physicians, American College of Physicians, and Infectious Diseases Society of America
Disclosure: Nothing to disclose.

Further Reading

© 1994- by Medscape.
All Rights Reserved
(http://www.medscape.com/public/copyright)